Literature DB >> 11216649

A follicle-stimulating hormone receptor ecto-domain epitope that is a target for receptor immunoneutralization yet does not affect ligand contact and activation.

X Liu1, G M Butterstein, B Lindau-Shepard, H A Brumberg, J A Dia.   

Abstract

The follicle-stimulating hormone receptor (FSHR) large extracellular domain suggests that interaction of ligand with receptor is likely to be complex. Residues 265-296 of the FSHR are part of a sequence primarily nonhomologous with other glycoprotein hormone receptors. A reasonable hypothesis is that this sequence of the FSHR plays a role in binding FSH. Flow cytometry studies of this region revealed that antibody X179 against peptide R265-S296 binds to human FSHR expressed by CHO cells and can be competed against by preincubating the cells with hFSH. These results suggested that the region corresponding to residues 265-296 in the extracellular domain of the FSHR is involved in binding to hormone. To test this hypothesis 10 scanning alanine mutants of rFSHR at the 265-296 epitope were generated, and the binding characteristics of these mutants were studied. Their affinity constants for 125I-hFSH did not deviate greatly from that of wild-type FSHR, in which some mutants exhibited an approximately two- to threefold reduction in Ka compared to wild-type receptor, and no mutation abolished signal transduction. These results lead to rejection of the hypothesis that this region contains residues critical for conveying hormone specificity and receptor-dependent hormone action.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11216649     DOI: 10.1385/endo:13:3:361

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.633


  25 in total

1.  Derivation of functional antagonists using N-terminal extracellular domain of gonadotropin and thyrotropin receptors.

Authors:  Y Osuga; M Kudo; A Kaipia; B Kobilka; A J Hsueh
Journal:  Mol Endocrinol       Date:  1997-10

2.  Topographic analysis of the alpha-subunit of human follicle-stimulating hormone using site-specific antipeptide antisera.

Authors:  R S Weiner; T T Andersen; J A Dias
Journal:  Endocrinology       Date:  1990-08       Impact factor: 4.736

3.  Comparison of a structural and a functional epitope.

Authors:  B C Cunningham; J A Wells
Journal:  J Mol Biol       Date:  1993-12-05       Impact factor: 5.469

4.  Expression of extracellular domain peptides of the FSH receptor and their effect on receptor-ligand interactions in vitro.

Authors:  S C Sharma; J F Catterall
Journal:  Mol Cell Endocrinol       Date:  1995-11-30       Impact factor: 4.102

5.  A polyclonal antibody to a synthetic peptide derived from the rat follicle-stimulating hormone receptor reveals the recombinant receptor as a 74-kilodalton protein.

Authors:  J Quintana; R W Hipkin; M Ascoli
Journal:  Endocrinology       Date:  1993-11       Impact factor: 4.736

6.  Identification of hormone-binding regions of the luteinizing hormone/human chorionic gonadotropin receptor using synthetic peptides.

Authors:  P C Roche; R J Ryan; D J McCormick
Journal:  Endocrinology       Date:  1992-07       Impact factor: 4.736

7.  Localization and synthesis of the hormone-binding regions of the human thyrotropin receptor.

Authors:  M Z Atassi; T Manshouri; S Sakata
Journal:  Proc Natl Acad Sci U S A       Date:  1991-05-01       Impact factor: 11.205

8.  Accessibility of rat and human follitropin receptor primary sequence (R265-S296) in situ.

Authors:  X Liu; J A DePasquale; M D Griswold; J A Dias
Journal:  Endocrinology       Date:  1994-08       Impact factor: 4.736

9.  DNA sequencing with chain-terminating inhibitors.

Authors:  F Sanger; S Nicklen; A R Coulson
Journal:  Proc Natl Acad Sci U S A       Date:  1977-12       Impact factor: 11.205

10.  Amino-terminal leucine-rich repeats in gonadotropin receptors determine hormone selectivity.

Authors:  T Braun; P R Schofield; R Sprengel
Journal:  EMBO J       Date:  1991-07       Impact factor: 11.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.